Retinal dysfunction in cancer-associated retinopathy is improved by Ca2+ antagonist administration and dark adaptation

Investigative Ophthalmology and Visual Science

Volumn 42, Issue 11, 2001, Pages 2589-2595

  Ohguro, H ^a   Ogawa, K I ^a   Maeda, T ^a   Maruyama, I ^a   Maeda, A ^a   Takano, Y ^a   Nakazawa, M ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; NILVADIPINE; PROTEIN ANTIBODY; RECOVERIN; RECOVERIN ANTIBODY; RHODOPSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CONTROLLED STUDY; DARK ADAPTATION; DRUG EFFICACY; ELECTRORETINOGRAPHY; HISTOPATHOLOGY; ILLUMINATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RETINOPATHY;

ANIMALS; ANTIBODIES; ANTIGENS, NEOPLASM; CALCIUM CHANNEL BLOCKERS; CALCIUM-BINDING PROTEINS; DARK ADAPTATION; ELECTRORETINOGRAPHY; EYE PROTEINS; HIPPOCALCIN; INJECTIONS; INJECTIONS, INTRAPERITONEAL; LIGHT; LIPOPROTEINS; NERVE TISSUE PROTEINS; NIFEDIPINE; PARANEOPLASTIC SYNDROMES; PHOSPHORYLATION; PHOTORECEPTORS, VERTEBRATE; RATS; RATS, INBRED BN; RATS, INBRED LEW; RECOVERIN; RETINAL DISEASES; RHODOPSIN; VITREOUS BODY;

EID: 0034787950     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Blindness caused by photoreceptor degeneration as a remote effect of cancer
2. Occurrence of anti-retinal ganglion cell antibodies in patients with small cell cancer of the lung
3. Photoreceptor degeneration: Possible autoimmune disorder
4. An ultrastructural study of retinal photoreceptor degeneration associated with bronchial cancer
5. Paraneoplastic retinopathy
6. Management and monitoring of cancer-associated retinopathy
7. Antibody reactions with retina and cancer-associated antigens in 10 patients with cancer-associated retinopathy
8. A clinical triad to diagnose paraneoplastic retinopathy
9. The cancer-associated retinopathy antigen is a recoverin-like protein
10. A photoreceptor calcium-binding protein is recognized by autoantibodies obtained from patients with cancer-associated retinopathy
11. Rhodopsin phosphorylation as a mechanism of cyclic GMP phosphodiesterase regulation by S-modulin
12. Structural and enzymatic aspects of rhodopsin phosphorylation
13. Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy
14. Characterization of a small-cell-lung-carcinoma cell line from a patient with cancer-associated retinopathy
15. Intraperitoneal cultivation of small-cell carcinoma induces expression of the retinal cancer-associated retinopathy antigen
16. Lung cancer-induced blindness
17. Experimental cancer-induced retinopathy
18. Autoimmune basis for visual paraneoplastic syndrome in patients with small-cell cancer
19. Cancer-associated retinopathy (CAR) with autoantibodies reacting with retinal optic nerve, cancer cells
20. Both recoverin and hsc70 are found as autoantigens in patients with cancer-associated retinopathy
21. The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy
22. Anti-neurofilament antibodies in the sera of patients with small cell carcinoma of the lung and with visual paraneoplastic syndrome
23. Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo
24. Apoptotic retinal cell death induced by anti-recoverin autoantibodies of cancer-associated retinopathy
25. Antibodies to recoverin induce apoptosis of photoreceptor and bipolar cells in vivo
26. Mechanisms of photoreceptor cell death in cancer-associated retinopathy
27. Retinal cell death by light damage
28. Calcium, vascular smooth muscle, and calcium entry blockers in hypertension
29. Calcium antagonist and the peripheral circulation: Differences and similarities between PY 108-068, nicardipine, verapamil and diltiazem
30. New generation dihydropyridine calcium entry blockers: In search of greater selectivity for one tissue subtype
31. Quantitative relationship and photopic ERG to photoreceptor cell loss in light damaged rats
32. Light-induced apoptosis: Differential timing in the retina and pigment epithelium
33. Retinal photoreceptor dystrophies
34. Retinitis pigmentosa: Defined from a molecular point of view
35. Rhodopsin mutations in autosomal dominant retinitis pigmentosa
36. Mechanisms of rhodopsin inactivation in vivo as revealed by a COOH-terminal truncation mutant
37. High levels of rhodopsin phosphorylation in missense mutations of C-terminal region of rhodopsin
38. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma
39. Anti-neuronal antibodies and neurological paraneoplastic syndrome
40. Paraneoplastic cerebellar degeneration: A clinical comparison of patients with and without Purkinje cell cytoplasmic antibodies
41. Cancer-associated retinopathy vs. recoverin-associated retinopathy
42. Protective effects of flunarizine on ischemic injury in the rat retina
43. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent
44. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischemia to the retina
45. Retinitis pigmentosa: Rod photoreceptor rescue by a calcium-channel blocker in the rd mouse
46. The effect of calcium channel blocker diltiazem on photoreceptor degeneration in the rhodopsin Pro23His rat
47. 2+-antagonist on visual field in low-tension glaucoma
48. Calcium channel blockers in the management of low-tension and open-angle glaucoma
49. Nimodipine, a centrally active calcium antagonist, exerts a beneficial effect on contrast sensitivity in patients with normal-tension glaucoma
50. Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma
51. Antihypertensive effects of nilvadipine determined by ambulatory blood pressure monitoring
52. Comparison of the cardiovascular effect of FR34235, a new dihydropyridine, with other calcium antagonists
53. Effects of nilvadipine, a calcium antagonist, on rabbit ocular circulation and optic nerve head circulation in NTG subjects
54. Effects of systemic nilvadipine on preventing progression of visual field defect in normal-tension glaucoma